11月19日，吉贝尔盘中下跌2.00%，截至11:19，报29.33元/股，成交1997.77万元，换手率0.34%，总市 值58.49亿元。 分红方面，吉贝尔A股上市后累计派现4.76亿元。近三年，累计派现2.52亿元。 资金流向方面，主力资金净流出104.50万元，大单买入193.38万元，占比9.68%，卖出297.88万元，占比 14.91%。 机构持仓方面，截止2025年9月30日，吉贝尔十大流通股东中，财通优势行业轮动混合A（011201）位 居第九大流通股东，持股123.92万股，为新进股东。广发医疗保健股票A（004851）位居第十大流通股 东，持股95.90万股，为新进股东。 吉贝尔今年以来股价涨34.05%，近5个交易日跌5.99%，近20日跌8.00%，近60日跌21.28%。 责任编辑：小浪快报 资料显示，江苏吉贝尔药业股份有限公司位于江苏省镇江市高新技术产业开发园区，成立日期2001年11 月13日，上市日期2020年5月18日，公司主营业务涉及专业从事药品研发、生产、销售。主营业务收入 构成为：利可君片72.72%，尼群洛尔片14.20%，玉屏风胶囊4.88%，其他4.53%，醋氯 ...

证券之星消息，2025年11月14日吉贝尔（688566）发布公告称公司于2025年11月14日召开业绩说明会。 具体内容如下： 问：（1）公司的销售差异化这么大，有什么策略升其他区域的销售额？（2）尼群洛尔片效果这么好，有 什么销售策略打开市场？（3）公司上市五年了营收没有比较大的改变，特别是各个地区销售不平衡，如 果华南、华中地区的销售做到华东地区的80%，公司总体营收和利润都起来了。（4）公司有没有出海的 计划？ 答：目前，公司新工厂充分考虑未来市场需求，整体智能化水平较高，产能覆盖公司现有产品及在研产 品，有效满足公司业务发展需要。 答：从全国范围来看，公司产品存在销售区域发展不均衡，仍然有较大的空白市场。公司制定相关政策， 树立标杆，对标找差，完善竞争和激励机制，优化资源配置，进一步加强空白市场开发力度，挖掘增量市 场空间。 尼群洛尔片是国内首个一类复方抗高血压新药，在高血压伴高心率细分领域具体领先优势。近 年来，公司通过组建专门事业部、构建专家网络，加快推进尼群洛尔片在高血压伴高心率细分领域的推广 与运用，产品销售收入实现了持续较快增长。截至2025年9月底，尼群洛尔片覆盖医院总数7,000余家， ...

Core Viewpoint - The company is actively preparing the application materials for the new drug JJH201501 and is progressing with the subsequent processes while ensuring compliance with information disclosure obligations [1] Group 1 - The company is responding to investor inquiries regarding the status of the new drug application [1] - The company will disclose relevant information in accordance with regulations through designated media [1]

Core Viewpoint - The company is strategically investing in stem cell technology through equity stakes in two firms, focusing on innovation and future application potential [2] Group 1: Investment Strategy - The company has invested in Zhejiang Shengchuang Precision Medical Technology Co., Ltd. and Shanghai Aisaar Biotechnology Co., Ltd., both related to stem cell technology [2] - The investment decision will consider factors such as product innovation, technological advancement, and future application prospects [2] - The company emphasizes a cautious approach in selecting investment projects based on its development needs [2]

吉贝尔11月10日在互动平台表示，公司参股子公司浙江生创精准医疗科技有限公司正在研发的宫血间充 质干细胞注射液(SC01009) 适应症覆盖特发性肺纤维化、乙型肝炎后肝硬化失代偿期、轻、中度急性呼 吸窘迫综合征等疾病的治疗，其中特发性肺纤维化适应症正在开展Ⅱ期临床试验。 ...

Group 1 - The company is currently preparing the necessary materials for the new drug application of JJH201501 as per relevant requirements [1]

Core Viewpoint - The stock of Jibeier has experienced a decline of 2.02% on November 10, with a current price of 31.01 CNY per share, despite a year-to-date increase of 41.73% [1] Financial Performance - For the period from January to September 2025, Jibeier achieved a revenue of 704 million CNY, representing a year-on-year growth of 9.52%, and a net profit attributable to shareholders of 197 million CNY, which is a 12.80% increase compared to the previous year [2] - Cumulative cash dividends since the A-share listing amount to 476 million CNY, with 252 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jibeier is 7,742, an increase of 28.97% from the previous period, while the average circulating shares per person decreased by 22.46% to 25,759 shares [2] - The top ten circulating shareholders include new entrants such as Caitong Advantage Industry Rotation Mixed A and GF Healthcare Stock A, holding 1.2392 million shares and 959,000 shares respectively [3] Stock Market Activity - On November 10, Jibeier's trading volume reached 40.387 million CNY, with a turnover rate of 0.65% and a total market capitalization of 6.184 billion CNY [1] - The stock has seen a decline of 9.17% over the last five trading days, 6.60% over the last twenty days, and 1.30% over the last sixty days [1] Business Overview - Jibeier, established on November 13, 2001, and listed on May 18, 2020, is primarily engaged in the research, production, and sales of pharmaceuticals [1] - The main revenue sources include Likujun tablets (72.72%), Niqurol tablets (14.20%), Yupingfeng capsules (4.88%), and other products [1]

Core Viewpoint - The company Gibeal's new antidepressant drug JJH201501 has completed Phase III clinical trials, showing significant efficacy and safety advantages over existing treatments, particularly the commonly used drug Vortioxetine, addressing the unmet needs of approximately 95 million depression patients in China [1][4]. Group 1: Clinical Data and Efficacy - JJH201501 demonstrates superior efficacy compared to placebo and comparable efficacy to Vortioxetine at a lower dosage, with 10mg and 15mg doses showing significant improvement after 8 weeks of treatment [2][3]. - The drug's mechanism, based on deuterated drug development technology, allows for lower doses to achieve higher efficacy, enhancing patient exposure and prolonging the drug's half-life [2][3]. Group 2: Safety Profile - JJH201501 exhibits a competitive safety profile, with adverse reaction rates leading to permanent discontinuation being comparable to placebo and significantly lower than Vortioxetine, particularly regarding gastrointestinal side effects [2][3]. - Improved safety is expected to enhance medication adherence among patients requiring long-term treatment for depression [2][3]. Group 3: Market Potential - The global antidepressant market is substantial, with over 350 million patients worldwide and 95 million in China, indicating a significant unmet demand for effective treatments [4][5]. - JJH201501 is positioned to become a first-line treatment option in the antidepressant market, potentially driving growth for Gibeal if successfully approved and included in insurance coverage [4][6]. Group 4: Competitive Landscape - The current antidepressant market in China is dominated by imported original drugs and domestic generics, with a lack of innovative local products, positioning JJH201501 as a much-needed addition [4][5]. - The drug's expected long-term usage cycle, similar to that of Vortioxetine, supports its potential for sustained market growth [3][4].

Core Points - The company will hold an online investor briefing on November 14, 2025, from 15:00 to 16:00 to discuss its Q3 2025 performance and financial indicators [2][3][4] - Investors can submit questions in advance until November 13, 2025, at 16:00, and the company will address common concerns during the interactive session [2][4] - Key personnel attending the meeting include the Chairman, General Manager, CFO, Board Secretary, and an Independent Director [5] Meeting Details - The meeting will be conducted via text interaction on the Dongfang Caifu Roadshow platform [4][6] - Contact information for inquiries includes the Securities Investment Department, with a phone number and email provided [6] Additional Information - After the meeting, investors can access the main content and details of the briefing on the Dongfang Caifu Roadshow platform [6][7]

证券代码：688566 证券简称：吉贝尔 公告编号：2025-049 江苏吉贝尔药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2025 年 11 月 14 日（星期五）15:00-16:00 会议召开方式：线上文字互动 投资者可于 2025 年 11 月 13 日（星期四）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）发布《公司 2025 年第三季度报 告》，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财 务状况、发展理念，公司计划于 2025 年 11 月 14 日（星期五）15:00-16:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本 ...